Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

BACKGROUND Due to a dismal prognosis of advanced lung cancer, novel screening tools and more effective treatments are clearly needed. Lately, an increasing number of tumour-released angiogenic cytokines which affect vessel formation, tumour growth, invasion, and metastasis have been identified. Vascular endothelial growth factors (VEGFs) and basic fibroblast growth factor (bFGF) are among the most important angiogenic factors. Based on available literature, we have explored the mechanisms of angiogenesis and its prognostic significance in non-small cell lung cancer, estimated by microvessel density (MVD) and the presence of VEGF and bFGF in the tumour and blood from NSCLC patients. METHODS Several comprehensive Pubmed searches for the period January 1993 to May 2005 were performed using strategic combinations of the terms non-small cell lung cancer, angiogenesis, vascular endothelial growth factor, basic fibroblast growth factor, tumour expression, microvessel density, circulating, and serum. RESULTS NSCLC neoangiogenesis, as measured by MVD, and tumour expression of VEGF are poor prognostic factors for survival (MVD, HR 1.8-2.0; VEGF, HR 1.5). bFGF tumour expression is also associated with poor survival and more aggressive disease. When evaluating the prognostic impact of elevated VEGF levels in blood, 10 of 16 studies (63%) indicated a negative prognostic impact. Of five studies on the prognostic value of circulating bFGF, three studies reported a negative prognostic impact, while one indicated bFGF as a good prognostic factor and one was inconclusive. CONCLUSION Angiogenic factors are poor prognostic indicators for tumour aggressiveness and survival in NSCLC. Assessments of circulating levels of VEGF and possibly bFGF may be valuable future tools for treatment planning and monitoring of treatment effect and relapse. First, however, these blood tests need to be standardised and validated in large-scale prospective clinical trials.

[1]  A. Giatromanolaki,et al.  Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[3]  G. Watanabe,et al.  Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer. , 2004, Chest.

[4]  Y. Kameda,et al.  Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. , 2002, Oncology reports.

[5]  J. Winer,et al.  Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. , 1992, The Journal of clinical investigation.

[6]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[7]  K. Hiroshima,et al.  Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. , 2002, Lung cancer.

[8]  A. Schor,et al.  Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer , 2001, Journal of clinical pathology.

[9]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[10]  J. Isner,et al.  Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.

[11]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[12]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[13]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[14]  L. Orci,et al.  In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. , 1994, Experimental cell research.

[15]  T. Yamamoto,et al.  Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma. , 1996, Japanese journal of clinical oncology.

[16]  T. Horie,et al.  Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. , 2000, European journal of cancer.

[17]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[18]  K. Arimura,et al.  Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. , 2000, Chest.

[19]  K. O'Byrne,et al.  Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer , 2000, British Journal of Cancer.

[20]  Y. Fukushima,et al.  Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. , 1999, European journal of cancer.

[21]  T. Manabe,et al.  Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients , 2004, British Journal of Cancer.

[22]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[23]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[24]  G. Déléris,et al.  Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. , 2003, Current medicinal chemistry. Anti-cancer agents.

[25]  I. Stratford,et al.  Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. , 1997, British Journal of Cancer.

[26]  G. Neufeld,et al.  VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular Matrix* , 1997, The Journal of Biological Chemistry.

[27]  S. Hirohashi,et al.  Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[29]  G. Semenza,et al.  V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.

[30]  D. Gospodarowicz,et al.  Structural characterization and biological functions of fibroblast growth factor. , 1987, Endocrine reviews.

[31]  A. Yuan,et al.  Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Yung‐Chie Lee,et al.  Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Gomez,et al.  Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. , 1996, Cancer research.

[34]  G. Palade,et al.  Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.

[35]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[36]  Brem.  Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. , 1999, Cancer control : journal of the Moffitt Cancer Center.

[37]  T. Sugimura,et al.  Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. , 1991, Biochemical and biophysical research communications.

[38]  Y. Miller,et al.  Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  M. Volm,et al.  Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. , 1997, Anticancer research.

[40]  M. Greenblatt,et al.  Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. , 1968, Journal of the National Cancer Institute.

[41]  A. Larsson,et al.  Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. , 2003, Lung cancer.

[42]  D. Rifkin,et al.  Studies on the role of basic fibroblast growth factor in vivo: Inability of neutralizing antibodies to block tumor growth , 1990, Journal of cellular physiology.

[43]  G. Watanabe,et al.  The Combination Assay with Circulating Vascular Endothelial Growth Factor (VEGF)-C, Matrix Metalloproteinase-9, and VEGF for Diagnosing Lymph Node Metastasis in Patients With Non–Small Cell Lung Cancer , 2004, Annals of Surgical Oncology.

[44]  S. Kondo,et al.  Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. , 1994, Biochimica et biophysica acta.

[45]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[46]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[47]  Y. Fukushima,et al.  Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. , 1998, International journal of oncology.

[48]  Ikuo Inoue,et al.  A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. , 2002, Diabetes.

[49]  H. Kato,et al.  Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer , 2001, British Journal of Cancer.

[50]  Y. Nakanishi,et al.  The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  D. Mukhopadhyay,et al.  Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.

[52]  R. Sasada,et al.  Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. , 1991, Cancer research.

[53]  K. Eguchi,et al.  Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. , 1998, Anticancer research.

[54]  R. Friesel,et al.  Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  M. Volm,et al.  PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. , 1999, Anticancer research.

[56]  C. Heldin,et al.  Platelet-derived growth factor is angiogenic in vivo. , 1992, Growth factors.

[57]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[58]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[59]  Athens Greece,et al.  Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  L. Orci,et al.  Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. , 1992, Biochemical and biophysical research communications.

[61]  A. Gazdar,et al.  Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  K. O'Byrne,et al.  Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. , 1997, British Journal of Cancer.

[63]  N. Ferrara.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.

[64]  K. Yasumoto,et al.  Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. , 1998, The Journal of thoracic and cardiovascular surgery.

[65]  C. Angeletti,et al.  Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. , 1997, British Journal of Cancer.

[66]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[67]  E. Okajima,et al.  Frequent expression of the vascular endothelial growth factor in human non-small-cell lung cancers. , 1998, Japanese journal of clinical oncology.

[68]  H. Dvorak,et al.  Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation a , 1992, Annals of the New York Academy of Sciences.

[69]  M. Hidalgo,et al.  Angiogenesis inhibitors in clinical development for lung cancer. , 2002, Seminars in oncology.

[70]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[71]  J. Silverman,et al.  Vascular Endothelial Growth Factor Expression in Stage I Non-Small Cell Lung Cancer Correlates With Neoangiogenesis and a Poor Prognosis , 2001, Annals of Surgical Oncology.

[72]  H. W. Chalkley,et al.  Vasculae Reactions of Normal and Malignant Tissues in Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants , 1945 .

[73]  E. Brambilla,et al.  Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF‐R1‐Flt1 and VEGF‐R2‐Flk1/KDR) in non‐small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival , 1999, The Journal of pathology.

[74]  Jin-Hyuk Choi,et al.  Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. , 2001, Lung cancer.

[75]  M. Bottomley,et al.  Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. , 1998, Clinical science.

[76]  K. Miyazono,et al.  Purification and properties of an endothelial cell growth factor from human platelets. , 1987, The Journal of biological chemistry.

[77]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  A. Harris,et al.  ‘Invading edge vs. inner’ (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non‐small cell lung cancer , 2000, The Journal of pathology.

[79]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[80]  J. Nikliński,et al.  Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. , 2001, Lung cancer.

[81]  Stefania Basili,et al.  Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. , 2003, Thrombosis and haemostasis.

[82]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Y. Maniwa,et al.  Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. , 1998, Chest.

[84]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[85]  J. Verdebout,et al.  [VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. , 2002, Revue des maladies respiratoires.

[86]  G. Vohwinkel,et al.  Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  F. Bayard,et al.  Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect* , 1997, The Journal of Biological Chemistry.

[88]  A. Harris,et al.  Platelet‐derived endothelial cell growth factor (Thymidine Phosphorylase) expression in lung cancer , 1997, The Journal of pathology.

[89]  N. Weidner,et al.  Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow , 1998, The Journal of pathology.

[90]  S. Abe,et al.  Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[92]  V. Pravica,et al.  Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. , 1999, Human immunology.

[93]  A. N. Corps,et al.  A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.

[94]  M. Volm,et al.  Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. , 1996, British Journal of Cancer.

[95]  G. Fontanini,et al.  The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. , 1999, Human pathology.

[96]  S. Fox,et al.  Thymidine phosphorylase is angiogenic and promotes tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Y. Kido.  Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. , 2001, The Kurume medical journal.

[98]  S. Hamilton-Dutoit,et al.  Patterns of angiogenesis in nonsmall‐cell lung carcinoma , 2001, Cancer.

[99]  G. Watanabe,et al.  Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. , 2001, Oncology reports.

[100]  J. Folkman,et al.  Angiogenesis and angiogenesis inhibition: an overview. , 1997, EXS.

[101]  R. Haba,et al.  Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[102]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[103]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[104]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[105]  J. Trapé,et al.  Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer. , 2003, Clinical chemistry.

[106]  C. Angeletti,et al.  Modulation of neoangiogenesis in bronchial preneoplastic lesions. , 1999, Oncology reports.

[107]  C. Angeletti,et al.  Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  Seung-Ha Park,et al.  The Relationship between Serum VEGF Concentration and Prognosis of Lung Cancer , 2003, The Korean journal of internal medicine.

[109]  N. Weidner.  Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.

[110]  S. Takeno,et al.  Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma , 2003, Cancer.

[111]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[112]  M. Volm,et al.  Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors. , 1998, International journal of oncology.

[113]  G. Watanabe,et al.  The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer , 2001, British Journal of Cancer.

[114]  B. Martin,et al.  VEGF et survie des patients atteints d'un cancer pulmonaire , 2002 .

[115]  M. Volm,et al.  Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. , 1997, European journal of cancer.

[116]  L. Ellis,et al.  Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. , 1998, European journal of cancer.

[117]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[118]  W. Jelkmann,et al.  Pitfalls in the measurement of circulating vascular endothelial growth factor. , 2001, Clinical chemistry.

[119]  S. Fan,et al.  Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  K. O'Byrne,et al.  Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. , 1998, British Journal of Cancer.

[121]  W. Kaelin,et al.  von Hippel-Lindau disease. , 1997, Medicine.

[122]  W. Renner,et al.  A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels , 2000, Journal of Vascular Research.

[123]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[124]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[125]  M. Volm,et al.  Prognostic value of vascular endothelial growth factor and its receptor Flt‐1 in squamous cell lung cancer , 1997, International journal of cancer.

[126]  M. Liao,et al.  Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. , 2001, Lung cancer.

[127]  A. Larsson,et al.  Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. , 2002, Lung cancer.

[128]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[129]  H. Okumura,et al.  The activity and expression of thymidine phosphorylase in human solid tumours. , 1996, European journal of cancer.

[130]  E. Maltezos,et al.  VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. , 2004, Lung cancer.

[131]  W. Silverman,et al.  Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[132]  A. N. Corps,et al.  Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[133]  G. Conn,et al.  Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[134]  A. Prats,et al.  Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes , 1995, Molecular and Cellular Biology.

[135]  H. Verheul,et al.  Platelet: transporter of vascular endothelial growth factor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[136]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[137]  A. Sommer,et al.  Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[138]  K. Nishikawa,et al.  Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[139]  A. Ullrich,et al.  Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.

[140]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[141]  C. Angeletti,et al.  Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. , 1998, European journal of cancer.

[142]  S. Akiyama,et al.  Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. , 1995, Cancer research.

[143]  M. Tamura,et al.  Serum vascular endothelial growth factor‐C level in patients with primary nonsmall cell lung carcinoma , 2003, Cancer.

[144]  D. Gospodarowicz,et al.  Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells. , 1989, The EMBO journal.

[145]  T. Veikkola,et al.  VEGFs, receptors and angiogenesis. , 1999, Seminars in cancer biology.

[146]  Heikki Joensuu,et al.  Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. , 2002, Cancer research.

[147]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[148]  R. Muraoka,et al.  Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. , 1998, The Annals of thoracic surgery.

[149]  Joan W. Miller,et al.  Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. , 1996, Archives of ophthalmology.

[150]  L. Liotta,et al.  Tumor invasion and metastases: biochemical mechanisms. , 1988, Cancer treatment and research.

[151]  F. Shepherd,et al.  Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. , 2003, Lung cancer.

[152]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[153]  G. Gastl,et al.  Platelets and VEGF blood levels in cancer patients , 1999, British Journal of Cancer.

[154]  K. Ueno,et al.  Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. , 2001, Lung cancer.

[155]  N. Bouck,et al.  How tumors become angiogenic. , 1996, Advances in cancer research.

[156]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[157]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[158]  M. Oda,et al.  Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[159]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[160]  A. Harris,et al.  Platelet‐derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study , 1995, The Journal of pathology.

[161]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[162]  B. Vincenzi,et al.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer , 2004, Journal of Clinical Pathology.

[163]  A. Harris,et al.  A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: Is the current literature meaningful? , 2004, Clinical & Experimental Metastasis.

[164]  M. Tsao,et al.  Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[165]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[166]  A. Larsson,et al.  Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. , 1998, Anticancer research.

[167]  M. Knoth,et al.  Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. , 1968, Journal of the National Cancer Institute.

[168]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[169]  A. Harris,et al.  Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.

[170]  J. Verdebout,et al.  The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2002, British Journal of Cancer.

[171]  D. Hanahan,et al.  Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma , 1991, Cell.

[172]  G. Celik,et al.  The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. , 2004, Respiratory medicine.